The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 17, 2020
Filed:
Jan. 11, 2019
Applicant:
Nanjing Innocare Pharma Tech Co., Ltd., Nanjing, CN;
Inventors:
Assignee:
Nanjing InnoCare Pharma Tech Co., Ltd., Nanjing, CN;
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/14 (2006.01); C07D 401/12 (2006.01); C07D 213/75 (2006.01); C07D 413/14 (2006.01); A61P 35/00 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/444 (2006.01); A61K 31/4545 (2006.01); A61K 31/496 (2006.01); C07D 213/84 (2006.01);
U.S. Cl.
CPC ...
C07D 401/14 (2013.01); A61K 31/444 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61P 35/00 (2018.01); C07D 213/75 (2013.01); C07D 213/84 (2013.01); C07D 401/12 (2013.01); C07D 413/14 (2013.01);
Abstract
The present invention relates to a heterocyclic compound, a pharmaceutical composition containing the same, a preparation method thereof, and use thereof as a fibroblast growth factor receptor (FGFR) inhibitor. The compound is a heterocyclic compound as shown in Formula I, or a pharmaceutically acceptable salt, prodrug, solvent compound, polymorph, isomer or stable isotopic derivative thereof. The present invention further relates to use of the compound for the treatment or prevention of related diseases which are FGFR-mediated such as cancer, and a method for applying the compound to treat said diseases.